Braidwell’s Arcutis Biotherapeutics ARQT Stock Holding History

Braidwell’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,300,000	Closed	-$12.9M	–	77
2024 Q1	$12.9M	Buy	+1,300,000	New	+$9.7M	0.42%	58

Other funds holding ARQT

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Braidwell's ARQT Position: Q2 2024 in Review

Braidwell sold out of Arcutis Biotherapeutics (ARQT) in Q2 2024, closing a stake of 1,300,000 shares — an estimated $12.9M sold.

Braidwell first reported a position in ARQT in Q1 2024 and held it in 1 quarter. The position peaked at $12.9M in Q1 2024. 186 funds tracked by Wall St. Rank hold ARQT as of Q2 2024.

Braidwell reported no remaining Arcutis Biotherapeutics position as of Q2 2024 after selling out during the quarter.
Braidwell sold 1,300,000 Arcutis Biotherapeutics shares in Q2 2024, an estimated $12.9M.
Braidwell first reported a position in Arcutis Biotherapeutics in Q1 2024 and held it in 1 quarter.
Braidwell's Arcutis Biotherapeutics position peaked at $12.9M in Q1 2024.
186 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2024.

Based on Braidwell's 13F filing for Q2 2024, filed 14 Aug 2024.